OraSure Technologies reports Q3 revenue of $27.1 million

Reuters11-06
OraSure Technologies reports Q3 revenue of $27.1 million

OraSure Technologies Inc. reported net revenues of $27.1 million for the third quarter of 2025, down from $39.9 million in the same period of 2024. Gross profit for the quarter was $11.8 million, compared to $17.1 million in the third quarter of 2024. For the first nine months of 2025, net revenues were $88.3 million, a decrease from $148.4 million in the same period of 2024. The company provided fourth quarter 2025 revenue guidance in the range of $25 million to $28 million, with less than $0.1 million expected from COVID-19 testing. Recent business developments included signing a definitive agreement to acquire BioMedomics, adding the SickleSCAN rapid test for sickle cell disease to OraSure's portfolio, and extending its relationship with the Together Take Me Home program to distribute HIV self-tests.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OraSure Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569741-en) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment